Outset Medical, Inc. (OM)

Outset Medical, Inc. designs and manufactures the Tablo Hemodialysis System, an integrated platform that combines water purification, dialysate production, and digital analytics into a single device. The company sells both the hardware and the consumables required for ongoing dialysis treatments, targeting hospitals, dialysis clinics, and patients seeking home-based kidney replacement therapy. With more than 1,000 care sites now operating Tablo systems across the United States, Outset has established itself as a disruptor in a market historically dominated by large dialysis service providers and established device manufacturers.

Building the System from First Principles

Outset began as Home Dialysis Plus in 2003 in San Jose, California, founded with the vision of making dialysis simpler and more accessible. The company rebranded to Outset Medical in 2015 and spent years developing Tablo, a hemodialysis system designed from the ground up to address longstanding complexity in dialysis delivery. Traditional hemodialysis setups require separate devices for water purification and dialysate mixing, along with extensive operator training and complex logistics. Tablo consolidated these functions into a single, modular unit that could be deployed in diverse settings—large dialysis centers, hospitals, long-term care facilities, and eventually patients’ homes.

The FDA cleared Tablo for use in in-center and satellite dialysis settings in November 2016. The company’s biggest milestone came in April 2020 when Tablo became the first hemodialysis system approved for use in patients’ homes, opening an entirely new addressable market beyond traditional clinics. Subsequent regulatory expansions, including clearance for Tablo with prefiltration technology in 2024, have broadened the system’s clinical capabilities.

The Revenue Engine: Hardware and High-Margin Consumables

Outset operates a razor-and-blade business model. The Tablo console represents the initial capital expenditure; the recurring engine comes from consumables—cartridges, filters, and other disposables required for each dialysis session. Patients typically undergo dialysis three times per week for four to five hours per session, generating predictable, recurring consumption.

In 2025, Outset reported total revenue of $119.5 million, up 5% from the prior year. The company guided for 2026 revenue of $125–$130 million, implying continued mid-single-digit growth. Within that total, consumables and services—the recurring revenue portion—grew 11% year-over-year in Q2 2025, driven by 17% growth in consumable revenue specifically. This bifurcation between slower console placements and faster-growing consumables reflects the company’s transition from a growth-stage hardware play into a consumables-driven recurring revenue business.

Gross margins remain a key competitive advantage. Outset has guided for non-GAAP gross margins in the low- to mid-40% range for 2026, reflecting the high incremental margin on consumables and the benefit of scale as installed consoles grow.

The Insourcing Thesis: Why Dialysis Is Moving

Historically, kidney replacement therapy in the United States has been centralized: large dialysis chains like DaVita and Fresenius Medical Care operate thousands of clinics, bill insurers for treatments, and control the patient experience. Outset’s strategy hinges on reversing that trend. The “insourcing” movement—shifting dialysis back into hospitals, health systems, and eventually homes—creates demand for systems that are simpler to operate and cheaper to maintain than legacy alternatives.

Three factors drive this shift. First, home dialysis and in-hospital dialysis appeal to integrated health systems seeking to diversify revenue and reduce dependency on large dialysis chains. Second, patients often prefer treatment at home, where they have greater autonomy and can sometimes extend treatment duration for better clinical outcomes. Third, outcome data increasingly supports dialysis intensification and home-based modalities; data presented at Kidney Week 2025 showed that one insourced Tablo program at a large Florida hospital achieved a 94% reduction in serious cardiac or respiratory events over five years.

Outset has grown its installed base to more than 1,000 care sites running Tablo systems, performing roughly 1 million treatments per year and more than 3 million cumulative treatments to date. This base spans hospitals, dialysis centers, and home patients, and it continues to expand.

Products and Revenue Mix

This segmentation underscores Outset’s transition from a device company to a recurring revenue business. As the installed base stabilizes, console revenue should plateau, but consumable revenue will continue to climb as utilization increases at each site and new sites come online.

Challenges in a Concentrated Market

Outset competes against entrenched rivals. Fresenius Medical Care and DaVita together control roughly 70% of the U.S. dialysis market and have vast dialysis center networks, established relationships with health systems and payers, and scale advantages in manufacturing and distribution. Baxter International, a diversified medical device company, also sells hemodialysis systems. These competitors have decades of installed base and switching costs that favor incumbents.

Outset’s path to scale depends on execution at several levels: continued product innovation (expanded indications, enhanced features), retention and expansion within existing accounts, and geographic and demographic expansion. The company has also faced operational headwinds, including supply chain delays and competitive pricing pressure in certain markets. Net cash burn has improved markedly—2025 operating cash outflow was below $50 million, compared to $116 million in 2024—but the company remains pre-cash-flow-positive and dependent on execution against its growth plan.

Reimbursement is another structural risk. Most dialysis treatments are paid by Medicare and private insurers. Changes to dialysis reimbursement rates or bundled payment models could affect the economics of both insourcing adoption and Outset’s consumable pricing. The FDA also retains ongoing authority over device labeling and indications, so regulatory setbacks could slow expansion into new patient populations or care settings.

The Path Forward

Outset is pursuing several vectors of growth. The home dialysis market remains small but is expanding as outcomes improve and patient awareness grows. In-hospital and long-term care insourcing continues to accelerate as health systems invest in infrastructure. International expansion, though currently modest, presents long-term optionality. The company’s electronic health record integrations and data analytics platform, while small today, position it to play a role in the shift toward outcome-based dialysis care.

For investors and analysts, the key metrics to monitor are console placements (which indicate adoption momentum), consumable revenue growth (which reveals utilization and pricing power), gross margin expansion (a sign of manufacturing scale and mix improvement), and cash burn (showing progress toward sustainability). The 10-K filed annually with the SEC provides detailed segment information, quarterly earnings releases track adoption metrics, and investor presentations outline product roadmaps and market strategy.

Outset’s long-term thesis rests on the premise that dialysis will become less centralized and more diversified across hospitals, clinics, and homes, and that Tablo’s engineering and ease of use will win market share in that shift. Whether the company achieves profitable scale will depend on the speed of that transition, its ability to defend unit economics against larger competitors, and its execution against a challenging cash burn profile.